Dmytro Starenki1, Jong-In Park. 1. Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Abstract
CONTEXT: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the RET proto-oncogene. For MTC therapy, the U.S. Food and Drug Administration recently approved vandetanib and cabozantinib, multikinase inhibitors targeting RET and other tyrosine kinase receptors of vascular endothelial growth factor, epidermal growth factor, or hepatocyte growth factor. Nevertheless, not all patients with the progressive MTC respond to these drugs, requiring the development of additional therapeutic modalities that have distinct activity. OBJECTIVE: We aimed to evaluate mitochondria-targeted carboxy-proxyl (Mito-CP), a mitochondria-targeted redox-sensitive agent, for its tumor-suppressive efficacy against MTC. DESIGN: In vitro cultures of 2 human MTC cell lines, TT and MZ-CRC-1, and TT xenografts in mice were treated with Mito-CP in comparison with vandetanib. The effects on cell survival/death, RET expression, mitochondrial integrity, and oxidative stress were determined. RESULTS: Contrary to vandetanib, Mito-CP induced RET downregulation and strong cytotoxic effects in both cell lines in vitro, including caspase-dependent apoptosis. These effects were accompanied by mitochondrial membrane depolarization, decreased oxygen consumption, and increased oxidative stress in cells. Intriguingly, Mito-CP-induced cell death, but not RET downregulation, was partially inhibited by the reactive oxygen species scavenger, N-acetyl-cysteine, indicating that Mito-CP mediates tumor-suppressive effects via redox-dependent as well as redox-independent mechanisms. Orally administered Mito-CP effectively suppressed TT xenografts in mice, with an efficacy comparable to vandetanib and relatively low toxicity to animals. CONCLUSION: Our results suggest that Mito-CP can effectively suppress MTC cell growth/survival via a mechanism distinct from vandetanib effects. Mitochondrial targeting may be a potential strategy for MTC therapy.
CONTEXT: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the RET proto-oncogene. For MTC therapy, the U.S. Food and Drug Administration recently approved vandetanib and cabozantinib, multikinase inhibitors targeting RET and other tyrosine kinase receptors of vascular endothelial growth factor, epidermal growth factor, or hepatocyte growth factor. Nevertheless, not all patients with the progressive MTC respond to these drugs, requiring the development of additional therapeutic modalities that have distinct activity. OBJECTIVE: We aimed to evaluate mitochondria-targeted carboxy-proxyl (Mito-CP), a mitochondria-targeted redox-sensitive agent, for its tumor-suppressive efficacy against MTC. DESIGN: In vitro cultures of 2 human MTC cell lines, TT and MZ-CRC-1, and TT xenografts in mice were treated with Mito-CP in comparison with vandetanib. The effects on cell survival/death, RET expression, mitochondrial integrity, and oxidative stress were determined. RESULTS: Contrary to vandetanib, Mito-CP induced RET downregulation and strong cytotoxic effects in both cell lines in vitro, including caspase-dependent apoptosis. These effects were accompanied by mitochondrial membrane depolarization, decreased oxygen consumption, and increased oxidative stress in cells. Intriguingly, Mito-CP-induced cell death, but not RET downregulation, was partially inhibited by the reactive oxygen species scavenger, N-acetyl-cysteine, indicating that Mito-CP mediates tumor-suppressive effects via redox-dependent as well as redox-independent mechanisms. Orally administered Mito-CP effectively suppressed TT xenografts in mice, with an efficacy comparable to vandetanib and relatively low toxicity to animals. CONCLUSION: Our results suggest that Mito-CP can effectively suppress MTC cell growth/survival via a mechanism distinct from vandetanib effects. Mitochondrial targeting may be a potential strategy for MTC therapy.
Authors: R Michael Tuttle; Douglas W Ball; David Byrd; Gilbert H Daniels; Raza A Dilawari; Gerard M Doherty; Quan-Yang Duh; Hormoz Ehya; William B Farrar; Robert I Haddad; Fouad Kandeel; Richard T Kloos; Peter Kopp; Dominick M Lamonica; Thom R Loree; William M Lydiatt; Judith McCaffrey; John A Olson; Lee Parks; John A Ridge; Jatin P Shah; Steven I Sherman; Cord Sturgeon; Steven G Waguespack; Thomas N Wang; Lori J Wirth Journal: J Natl Compr Canc Netw Date: 2010-05 Impact factor: 11.908
Authors: Gang Cheng; Marcos Lopez; Jacek Zielonka; Andrew D Hauser; Joy Joseph; Donna McAllister; J Jordi Rowe; Sonia L Sugg; Carol L Williams; Balaraman Kalyanaraman Journal: Cancer Biol Ther Date: 2011-10-15 Impact factor: 4.742
Authors: R Morisi; M Celano; E Tosi; S Schenone; M Navarra; E Ferretti; G Costante; C Durante; G Botta; M D'Agostino; C Brullo; S Filetti; M Botta; D Russo Journal: J Endocrinol Invest Date: 2007-11 Impact factor: 4.256
Authors: Daniel L Gustafson; Erica L Bradshaw-Pierce; Andrea L Merz; Joseph A Zirrolli Journal: J Pharmacol Exp Ther Date: 2006-04-27 Impact factor: 4.030
Authors: Gantumur Battogtokh; Yeon Su Choi; Dong Seop Kang; Sang Jun Park; Min Suk Shim; Kang Moo Huh; Yong-Yeon Cho; Joo Young Lee; Hye Suk Lee; Han Chang Kang Journal: Acta Pharm Sin B Date: 2018-05-18 Impact factor: 11.413
Authors: Gang Cheng; Jacek Zielonka; Donna McAllister; Micael Hardy; Olivier Ouari; Joy Joseph; Michael B Dwinell; Balaraman Kalyanaraman Journal: Cancer Lett Date: 2015-05-21 Impact factor: 8.679
Authors: Pui-Kei Wu; Seung-Keun Hong; Wenjing Chen; Andrew E Becker; Rebekah L Gundry; Chien-Wei Lin; Hao Shao; Jason E Gestwicki; Jong-In Park Journal: Sci Signal Date: 2020-03-10 Impact factor: 8.192
Authors: Kathleen A Boyle; Jonathan Van Wickle; R Blake Hill; Adriano Marchese; Balaraman Kalyanaraman; Michael B Dwinell Journal: J Biol Chem Date: 2018-08-07 Impact factor: 5.157